Feedback / Questions
FK-PC101 - CellVax Therap
https://www.prnewswire.com/news-releases/theragent-and-cellvax-therapeutics-announce-first-patient-dosed-in-phase-2-trial-of-fk-pc101-a-novel-personalized-cancer-immunotherapy-302300746.html
Nov 11, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next